FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3117235087> ?p ?o ?g. }

• W3117235087 endingPage "e038411" @default.
• W3117235087 startingPage "e038411" @default.
• W3117235087 abstract "Objectives To establish the feasibility of a definitive randomised controlled trial of Systemic Autism-related Family Enabling (SAFE), an intervention for families of children with autism. Design A randomised, controlled, multicentred feasibility study. Setting Participants were identified from three National Health Service (NHS) diagnosing centres in Plymouth and Cornwall and a community pathway. Participants 34 families of a child with a diagnosis of autism severity level 1 or 2 between 3 and 16 years. Four families were lost to follow-up. Interventions SAFE is a manualised five-session family therapy-based intervention delivered over 16 weeks and designed for families of children with autism. SAFE involves families attending five 3-hour sessions led by systemic practitioners. Primary and secondary outcome measures The proposed primary outcome measure was the Systemic CORE 15 (SCORE-15). Proposed secondary outcome measures: Patient Health Questionnaire-Somatic Anxiety Depressive Symptoms, the Coding of Attachment-Related Parenting for use with children with Autism, the Child Behaviour Checklist (CBCL), the Reflective Functioning Questionnaire (RFQ) and the Caregiving Helplessness Questionnaire. Outcome measures were collected at baseline and 24 weeks post randomisation. Results All primary caregivers retained in the study completed the SCORE-15 at both time points. 34 of the target of 36 families were recruited and 88% of families were retained. Training for therapists was effective. Feedback revealed willingness to undergo randomisation. There was 100% attendance at appropriate sessions for core family members. The SCORE-15 showed reduction in scores for families receiving SAFE compared with controls suggesting positive change. Qualitative data also revealed that families found the study acceptable and families receiving SAFE experienced positive change. Feedback indicated that the SCORE-15 should be retained as a primary measure in a future trial, but secondary measures should be reduced. Conclusions This study indicates that a larger trial of SAFE is feasible. Findings suggest that SAFE can address current gaps in recommended care, can be confidently delivered by NHS staff and has potential as a beneficial treatment. Trial registration numbers ISCTRN83964946 and IRAS213527." @default.
• W3117235087 created "2021-01-05" @default.
• W3117235087 creator A5027546860 @default.
• W3117235087 creator A5046543103 @default.
• W3117235087 creator A5046679082 @default.
• W3117235087 creator A5047224925 @default.
• W3117235087 creator A5052266306 @default.
• W3117235087 creator A5055818114 @default.
• W3117235087 creator A5064907974 @default.
• W3117235087 creator A5068865896 @default.
• W3117235087 creator A5081989243 @default.
• W3117235087 creator A5089289582 @default.
• W3117235087 date "2020-12-01" @default.
• W3117235087 modified "2023-10-16" @default.
• W3117235087 title "SAFE, a new therapeutic intervention for families of children with autism: a randomised controlled feasibility trial" @default.
• W3117235087 cites W1520762614 @default.
• W3117235087 cites W1593447589 @default.
• W3117235087 cites W1698365488 @default.
• W3117235087 cites W1969090439 @default.
• W3117235087 cites W1979290264 @default.
• W3117235087 cites W1984589938 @default.
• W3117235087 cites W1984807202 @default.
• W3117235087 cites W1990460445 @default.
• W3117235087 cites W2007280276 @default.
• W3117235087 cites W2040207728 @default.
• W3117235087 cites W2042011817 @default.
• W3117235087 cites W2047924087 @default.
• W3117235087 cites W2059050738 @default.
• W3117235087 cites W2062559682 @default.
• W3117235087 cites W2066243939 @default.
• W3117235087 cites W2072525341 @default.
• W3117235087 cites W2087142890 @default.
• W3117235087 cites W2103627440 @default.
• W3117235087 cites W2108996609 @default.
• W3117235087 cites W2110143479 @default.
• W3117235087 cites W2125592770 @default.
• W3117235087 cites W2148420330 @default.
• W3117235087 cites W2148969439 @default.
• W3117235087 cites W2155427676 @default.
• W3117235087 cites W2156104108 @default.
• W3117235087 cites W2167253255 @default.
• W3117235087 cites W2219154285 @default.
• W3117235087 cites W2588028844 @default.
• W3117235087 cites W2946172905 @default.
• W3117235087 cites W4247665917 @default.
• W3117235087 cites W4251702589 @default.
• W3117235087 doi "https://doi.org/10.1136/bmjopen-2020-038411" @default.
• W3117235087 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7780715" @default.
• W3117235087 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33384385" @default.
• W3117235087 hasPublicationYear "2020" @default.
• W3117235087 type Work @default.
• W3117235087 sameAs 3117235087 @default.
• W3117235087 citedByCount "7" @default.
• W3117235087 countsByYear W31172350872021 @default.
• W3117235087 countsByYear W31172350872022 @default.
• W3117235087 countsByYear W31172350872023 @default.
• W3117235087 crossrefType "journal-article" @default.
• W3117235087 hasAuthorship W3117235087A5027546860 @default.
• W3117235087 hasAuthorship W3117235087A5046543103 @default.
• W3117235087 hasAuthorship W3117235087A5046679082 @default.
• W3117235087 hasAuthorship W3117235087A5047224925 @default.
• W3117235087 hasAuthorship W3117235087A5052266306 @default.
• W3117235087 hasAuthorship W3117235087A5055818114 @default.
• W3117235087 hasAuthorship W3117235087A5064907974 @default.
• W3117235087 hasAuthorship W3117235087A5068865896 @default.
• W3117235087 hasAuthorship W3117235087A5081989243 @default.
• W3117235087 hasAuthorship W3117235087A5089289582 @default.
• W3117235087 hasBestOaLocation W31172350871 @default.
• W3117235087 hasConcept C118552586 @default.
• W3117235087 hasConcept C134362201 @default.
• W3117235087 hasConcept C141071460 @default.
• W3117235087 hasConcept C15744967 @default.
• W3117235087 hasConcept C162324750 @default.
• W3117235087 hasConcept C168563851 @default.
• W3117235087 hasConcept C180747234 @default.
• W3117235087 hasConcept C1862650 @default.
• W3117235087 hasConcept C205778803 @default.
• W3117235087 hasConcept C27415008 @default.
• W3117235087 hasConcept C2778173179 @default.
• W3117235087 hasConcept C2779356329 @default.
• W3117235087 hasConcept C2780665704 @default.
• W3117235087 hasConcept C50522688 @default.
• W3117235087 hasConcept C512399662 @default.
• W3117235087 hasConcept C558461103 @default.
• W3117235087 hasConcept C70410870 @default.
• W3117235087 hasConcept C71924100 @default.
• W3117235087 hasConceptScore W3117235087C118552586 @default.
• W3117235087 hasConceptScore W3117235087C134362201 @default.
• W3117235087 hasConceptScore W3117235087C141071460 @default.
• W3117235087 hasConceptScore W3117235087C15744967 @default.
• W3117235087 hasConceptScore W3117235087C162324750 @default.
• W3117235087 hasConceptScore W3117235087C168563851 @default.
• W3117235087 hasConceptScore W3117235087C180747234 @default.
• W3117235087 hasConceptScore W3117235087C1862650 @default.
• W3117235087 hasConceptScore W3117235087C205778803 @default.
• W3117235087 hasConceptScore W3117235087C27415008 @default.
• W3117235087 hasConceptScore W3117235087C2778173179 @default.
• W3117235087 hasConceptScore W3117235087C2779356329 @default.

• next